Description:
Canagliflozin is a sodium/glucose cotransporter 2 (SGLT2) inhibitor. Canagliflozin has been shown to dose dependently reduce calculated renal threshold for glucose excretion and increase urinary glucose excretion. Canagliflozin is a candidate for the treatment of type 2 diabetes and obesity.
- Molecular Weight: 444.52
- Molecular Formula: C24H25FO5S
Purity: >98%
Canonical SMILES:
CC1=C(C=C(C=C1)C2C(C(C(C(O2)CO)O)O)O)CC3=CC=C(S3)C4=CC=C(C=C4)F
InChI:
InChI=1S/C24H25FO5S/c1-13-2-3-15(24-23(29)22(28)21(27)19(12-26)30-24)10-16(13)11-18-8-9-20(31-18)14-4-6-17(25)7-5-14/h2-10,19,21-24,26-29H,11-12H2,1H3/t19-,21-,22
InChIKey: XTNGUQKDFGDXSJ-ZXGKGEBGSA-N
- Boiling Point: 642.9±55.0°C at 760 mmHg
- Melting Point: 68-72°C
- Solubility: Soluble in DMSO (Slightly), Methanol (Slightly)
- Appearance: White to Light Yellow Solid
- Storage: Store at -20°C
Synonyms:
D-Glucitol, 1,5-anhydro-1-C-[3-[[5-(4-fluorophenyl)-2-thienyl]methyl]-4-methylphenyl]-, (1S)-; JNJ-24831754; TA-7284; JNJ 24831754; TA 7284; JNJ24831754; TA7284; (1S)-1,5-anhydro-1-C-[3-[[5-(4-fluorophenyl)-2-thienyl]methyl]-4-methylphenyl]-D-glucitol; (2S,3R,4R,5S,6R)-2-(3-((5-(4-Fluorophenyl)thien-2-yl)methyl)-4-methylphenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol; 1-(β-D-Glucopyranosyl)-4-methyl-3-[5-(4-fluorophenyl)-2-thienylmethyl]benzene; Invokana; JNJ 24831754ZAE; JNJ 28431754AAA
More details are to be found on supplier website
